

P33118USW**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**In re application of: **Eatherton et al.**Serial No.: **10/528,613**

Group Art Unit:

File Date: **February 28, 2006**

Examiner:

For: **Pyridine Derivatives As CB2 Receptor Modulators****Director of the U.S. Patent and Trademark Office****P.O. Box 1450****Alexandria, VA 22313-1450****SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Applicants hereby wish to notify the Examiner of the following co-pending applications:

10/524,469 filed 2/28/2006

10/524,470 filed 2/28/2006

10/528,592 (no official filing date)

10/597,527 (no official filing date)

10/597,476 (no official filing date)

10/597,474 (no official filing date)

10/597,521 (no official filing date)

10/597,524 (no official filing date)

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

☒ Copies of the references are enclosed: Ref. 3-22☐ Copies of the references were submitted in parent application _____ (37 CFR

1.98(d))

☐ A copy of the International Search Report which issued on International Application No. _____ is submitted herewith. All of the publications cited in the International Search Report are listed on the attached form PTO-1449 and Applicants understand that copies have been supplied to the U.S. Patent Office by the International Bureau.

A. ☐ The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).

OR

☒ The Information Disclosure Statement submitted herewith is being filed before the mailing of a first office action or after the filing of a Request For Continued Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).

B. ☐ The Information Disclosure Statement transmitted herewith is being filed after three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but before the mailing date of either:

- (1) a final action under § 1.113 or
- (2) a notice of allowance under § 1.311, whichever occurs first.

☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.


- ☐ Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$180.00).

- C. ☐ The Information Disclosure Statement transmitted herewith is being filed after a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which issued on International Publication No.

In accordance with the requirements of 37 CFR 1.97(d):

- ☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ Applicant hereby petitions for the consideration of the accompanying Information Disclosure Statement. 37 CFR 1.97(d)(ii).
- ☐ The petition fee set forth in § 1.17(i)(1) (\$130.00) is submitted herewith.
- ☒ Please charge any required fees to Deposit Account No. 07-1392.
- ☐ A duplicate copy of this paper is attached.

Respectfully Submitted,



J. Scott Young
Registration No. 45,582

Date: Jan 23 2007
GlaxoSmithKline
Corporate Intellectual Property
5 Moore Drive, P.O. Box 13398
Research Triangle Park, NC 27709-3398
Telephone: (919) 483-8160
Facsimile: (919) 483-7988

FORM PTO-1449				SERIAL NO.		10/528,613	
INFORMATION DISCLOSURE STATEMENT				FILING DATE		February 28, 2006	
				APPLICANT		Eatherton et al.	
				GROUP			
				EXAMINER			
				ATTORNEY DOCKET NO.		P33118USW	
U.S. PATENT DOCUMENTS							
Examiner Initials		Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
	1	5,112,820	5/12/1992	Ward et al.			
	2	5,925,768	7/20/1999	Sanofi et al.			
Continue on page _____							
FOREIGN PATENT DOCUMENTS							
		Document Number	Publication Date	Country	Class	Subclass	Translation Yes No
	3	EP 0569912	11/18/1993	EUROPE			X Abstract
	4	EP 0576357	12/29/1993	EUROPE			X Abstract
	5	FR 2839718	11/21/2003	FRANCE			X Abstract
	6	WO 97/09315	3/13/1997	WIPO			
	7	WO 00/39101	7/6/2000	WIPO			
	8	WO 02/04429	1/17/2002	WIPO			
	9	WO 02/060447	8/8/2002	WIPO			
	10	WO 02/66036	8/29/2002	WIPO			
	11	WO 04/00807	12/31/2003	WIPO			
	12	WO 04/002964	8/1/2004	WIPO			X Abstract
	13	WO 04/018433	3/4/2004	WIPO			
	14	WO 04/018434	3/4/2004	WIPO			
	15	WO 04/029026	4/8/2004	WIPO			
	16	WO 04/029027	4/8/2004	WIPO			
	17	WO 04/029204	4/8/2004	WIPO			
	18	WO 04/085385	10/7/2004	WIPO			
Continue on page _____							
OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)							
	19	Huffman, J.W. "The Search For Selective Ligands For The CB2 Receptor." Currently Pharmaceutical Design, Bentham Science Publishers, Vol. 6, No. 13, 2000, pgs. 1323-1337.					
	20	Souness, J.E. "Immunosuppressive And Anti-inflammatory Effect of Cyclic AMP." Immunopharmacology, 2000, 47/2-3; 127-162					
	21	Huang, Z., et al. "Next Generation of PDE4 Inhibitors." Current Opinion in Chemical Biology, 2001, pgs. 432-438.					
	22	Sullivan, R.W., et al. "2-Chloro-4-(trifluoromethyl)pyrimidine-5-N-(3',5'-bis(trifluoromethyl)phenyl)-carboxamic Potent Inhibitor of NF-KB-and AP-1-Mediated Gene Expression Identified Using Solution-Phase Combinatorial Chemistry; J. Med. Chem.; 1998; 41; 413-419.					
Continue on page _____							
EXAMINER					DATE CONSIDERED		
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.							